June 5, 2020
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: Tim Buchmiller
| Re: | Acer Therapeutics Inc. |
Registration Statement on Form S-1, as amended |
File No. 333-238192 |
Revised Request for Acceleration of Effectiveness |
Ladies and Gentlemen:
On June 3, 2020, Acer Therapeutics Inc. (the “Company”) submitted a request pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, to accelerate the effectiveness of the above-captioned registration statement on Form S-1 (as amended, the “Registration Statement”) so that such Registration Statement would become effective as of 4:00 p.m. Eastern Time on Thursday, June 4, 2020, or as soon thereafter as practicable. The Company hereby withdraws that prior request and hereby requests to accelerate the effectiveness of the Registration Statement so that it will become effective as of 4:00 p.m. Eastern Time on Friday, June 5, 2020, or as soon thereafter as may be practicable.
Very truly yours,
ACER THERAPEUTICS INC.
/s/ Harry S. Palmin
Harry S. Palmin
Chief Operating Officer and
Chief Financial Officer
| cc: | Mike Hird, Esq. |
Patty M. DeGaetano, Esq. |
One Gateway Center, Suite 351, 300 Washington Street, Newton, MA 02458
Phone: (844) 902-6100